Fundraising Fox
Kriya Therapeutics
Morrisville, US · Founded 2019 · Delaware corporation · 202 employees on LinkedIn · 17 known investors
Find your way into Kriya Therapeutics
Sign up to see every warm intro you have to Kriya Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Kriya Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Kriya Therapeutics is a biopharmaceutical company that develops and manufactures one-time gene therapies aimed at treating prevalent chronic diseases. It uses AAV-mediated gene therapy approaches across metabolic, neurodegenerative, and other disease areas.
Also known as Kriya
Founders & leadership
Kriya Therapeutics was founded in 2019 by Roger Jeffs, Fraser Wright, and Shankar Ramaswamy.
Investors · 17
How we know: the company's own site · funding news · bizjournals.com · Not right? Tell us
How we know: Premji Invest's portfolio page · the company's own site · finance.yahoo.com · Not right? Tell us
How we know: labiotech.eu · av.vc · Not right? Tell us
How we know: labiotech.eu · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: labiotech.eu · Not right? Tell us
How we know: Foresite Capital's portfolio page · labiotech.eu · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Holland Capital's portfolio page · Not right? Tell us
How we know: Narya Capital's portfolio page · labiotech.eu · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Also in the syndicate · 7
Reported raises · per SEC filings
Form D private placements$870.3M disclosed across 4 of 5 rounds · 2020–2025
▶$320.8MraisedSep 2025 · 10 investors · BiotechnologyRule 506(b)
- Neelaksh VarshneyDirector
- Michele StoneExecutive Officer
- Ilan OrenDirector
- Saira RamasastryDirector
- Ryan GallagherDirector
- Keith ManchesterDirector
- Katherine EadeExecutive Officer
- James MomtazeeDirector
- Akshay RaiDirector
- Shankar RamaswamyExecutive Officer, Director
- Curt HerbertsExecutive Officer
- Britt PettyExecutive Officer
- Roger JeffsDirector
- Brian FurmanskiExecutive Officer
- Trit GargDirector
- Offering amount
- $320.8M
- Amount sold
- $320.8M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$361.8MraisedJul 2023 · 29 investors · BiotechnologyRule 506(b)
- James MomtazeeDirector
- Neelaksh VarshneyDirector
- Roger JeffsDirector
- Dana JohnsonExecutive Officer
- Britt PettyExecutive Officer
- Trit GargDirector
- Michele StoneExecutive Officer
- Curt HerbertsExecutive Officer
- Keith ManchesterDirector
- Saira RamasastryDirector
- Shankar RamaswamyExecutive Officer, Director
- Ilan OrenDirector
- Offering amount
- $432M
- Amount sold
- $361.8M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$100MraisedJul 2021 · 36 investors · BiotechnologyRule 506(b)
- Daniel ChenExecutive Officer
- Ilan OrenDirector
- Keith ManchesterDirector
- Saira RamasastryDirector
- Roger JeffsDirector
- C.R. SincockDirector
- Dana JohnsonExecutive Officer
- James MomtazeeDirector
- Shankar RamaswamyExecutive Officer, Director
- Offering amount
- $100M
- Amount sold
- $100M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$87.6MraisedAug 2020 · 21 investors · BiotechnologyRule 506(b)
- Ilan OrenDirector
- Keith ManchesterDirector
- Roger JeffsDirector
- C.R. SincockDirector
- Shankar RamaswamyExecutive Officer, Director
- Offering amount
- $87.6M
- Amount sold
- $87.6M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Kriya Therapeutics is a biopharmaceutical company developing what it describes as "durable medicines" — treatments designed to be administered once and provide a lasting therapeutic effect — for chronic diseases. The company positions itself as an integrated organization in which research, development, and manufacturing operate together, incorporating production considerations into early-stage drug discovery rather than relying on outsourced or off-the-shelf processes.
Kriya's disclosed investigational pipeline spans five named programs across ophthalmic, endocrine, metabolic, hepatic, and neurological indications: KRIYA.825 for geographic atrophy, KRIYA.586 for thyroid eye disease, KRIYA.288 for type 1 diabetes, KRIYA.497 for steatotic liver disease, and KRIYA.748 for trigeminal neuralgia. The company has also reported preclinical work on an AAV-FGF21 gene therapy studied in aged mice. All of Kriya's medicines are investigational and have not been approved as safe or effective by any regulatory health authority.
Business model
Kriya develops proprietary one-time therapeutic candidates in-house and operates its own manufacturing capability, describing an integrated "product engine" that links research, development, and production rather than depending on external commodity processes.
Traction
The company has disclosed five named investigational programs. In June 2026 it announced selection for the FDA PreCheck Pilot Program, and in August 2026 it announced publication of preclinical data on an AAV-FGF21 gene therapy that extended health span and lifespan in aged mice.
Latest developments
In June 2026 Kriya announced it was selected for the FDA PreCheck Pilot Program, and in August 2026 it announced the publication of preclinical data showing that an AAV-FGF21 gene therapy extended health span and lifespan in aged mice.
▸Full profile — market position, technology, go-to-market, geography, risks & controversies
Market position
Kriya describes its portfolio as one of the industry's broadest collections of durable medicines, targeting chronic diseases that are conventionally treated with ongoing, repeat-administration therapies.
Kriya emphasizes vertical integration of discovery, development, and manufacturing; the incorporation of manufacturability into early drug design; and the use of its HOPSON structured manufacturing dataset together with computational and AI tools to inform successive programs.
Technology
Kriya's approach centers on durable, one-time-administration medicines, including AAV-based gene therapy candidates. The company states it has assembled a structured manufacturing dataset called HOPSON and applies artificial intelligence and applied computational tools to data generated from experiments and manufacturing runs, with the aim of improving process efficiency as more data accumulates. Each program is described as being engineered on the same underlying system so that development learnings carry across the portfolio.
Go-to-market
Patients with chronic diseases, addressed through indications including geographic atrophy, thyroid eye disease, type 1 diabetes, steatotic liver disease, and trigeminal neuralgia.
Geography
Kriya operates a campus in Research Triangle Park, North Carolina, housing scientists, engineers, and operators alongside its manufacturing activities.
Risks & controversies
All of Kriya's candidates are investigational and have not received regulatory approval as safe or effective, so the pipeline remains subject to clinical and regulatory outcomes.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
2 people who came through Kriya Therapeutics went on to found or lead other companies.
Related companies · 2
Companies working in the same space as Kriya Therapeutics.
Timeline · 2
launches, deals, and filingsKriya announced the publication of preclinical data reporting that an AAV-FGF21 gene therapy extended health span and lifespan in aged mice.
Kriya announced it had been selected for the U.S. FDA's PreCheck Pilot Program.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structure▸Research sources · 1
primary sources listed
- Kriya Therapeuticskriyatherapeutics.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Kriya Therapeutics do?
- Kriya Therapeutics develops one-time "durable medicines", including AAV gene therapies, for chronic diseases.
- Who founded Kriya Therapeutics?
- Kriya Therapeutics was founded by Roger Jeffs, Fraser Wright, Shankar Ramaswamy in 2019.
- Who are Kriya Therapeutics's investors?
- Kriya Therapeutics's investors include Patient Square Capital, Premji Invest, Alumni Ventures, Amplo Ventures, Anjost, Bluebird Ventures, Foresite Capital, Holland Capital and 2 more.
- How much funding has Kriya Therapeutics raised?
- Kriya Therapeutics has disclosed $870.3M raised across 4 of its 5 known rounds.
- Where is Kriya Therapeutics headquartered?
- Kriya Therapeutics is headquartered in Morrisville, US.